Facebook
Twitter
LinkedIn
Forward2025 Summit on Hematologic Cancers
This CME/CPE-accredited activity, the 2025 Summit on Hematologic Cancers, is a national meeting featuring leading experts in hematologic malignancies who will provide a comprehensive overview of current and emerging strategies for the management of acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, myeloproliferative neoplasms, multiple myeloma, and lymphoma. The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances along with case-based discussion in the field of hematologic malignancies. Expert faculty will aim to place the role of different therapeutic agents in a clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care.
Target Audience
- Cancer care professionals
- Practicing medical oncologists/hematologists
- Radiation oncologists
- Pathologists
- Medical oncology and hematology fellows
- Oncology nurses
- Nurse practitioners
- Physician assistants
- Pharmacists
ORGANIZING COMMITTEE
Course Director:
- Binay Shah, MD, MHA - Binaytara
Conference Chairs:
- Nitin Jain, MD - MD Anderson Cancer Center
- Navneet Majhail, MD, MS - Sarah Cannon
- Hetty Carraway, MD - Cleveland Clinic
- Shaji Kumar, MD - Mayo Clinic
Abstract Committee Chairs:
- Srinivas Tantravahi, MBBS, MRCP - University of Utah, Huntsman Cancer Institute
- Sangeetha Venugopal, MD, MS - University of Miami, Sylvester Comprehensive Cancer Center
Abstract Committee:
- Pallawi Torka, MD - Memorial Sloan Kettering Cancer Center
Learning Objectives
Upon successful completion of this educational activity, participants will be able to:
- Review strategies for initial therapy and therapies for relapsed disease for patients with various hematologic malignancies
- Outline efficacy and toxicities of small molecule inhibitors, monoclonal antibodies, antibody drug conjugates, T-cell redirecting bispecific antibodies, and CAR-T for the treatment of patients with hematologic malignancies
- Apply an individualized treatment plan for patients with ALL, AML, CML, MPN, MM, NHL, HL, based on patient- and disease-related factors
- Review evolving role of autologous and allogeneic stem cell transplantation in different hematologic malignancies
HOTEL INFORMATION
COMING SOON
DAY 1 – Friday, September 19, 2025
All times are listed in Central Daylight Time (CDT)
09:00 AM – 10:00 AM Breakfast, Registration & Exhibits
10:00 AM – 11:15 AM Session 1 - ALL
Session Chair: Nitin Jain, MD
10:00 AM – 10:15 AM Initial treatment of ALL in the older patient - Ryan Cassaday, MD
10:15 AM – 10:30 AM How best to incorporate CAR-T in Adult ALL - John Molina, MD, MEd
10:30 AM – 10:45 AM Treatment of Ph+/Ph-like ALL - Marlise Luskin, MD, MSCE
10:45 AM – 11:15 AM Q & A and Case-Based Panel Discussion - Guru Subramanian Guru Murthy, MD, MS
11:15 AM – 12:30 PM Session 2 - Aggressive Lymphomas
Session Chairs: Nirav Shah, MD
11:15 AM – 11:30 AM Updates in CAR-T therapy for aggressive lymphomas - Bhagirathbhai Dholaria, MD, MBBS
11:30 AM – 11:45 AM Focus on elderly patients with aggressive B-cell lymphomas
11:45 AM – 12:00 PM Outpatient management of CAR-T therapy recipients - Jeremy Pantin, MD, FACP
12:00 PM – 12:30 PM Q & A and Case-Based Discussion - Krish Patel, MD
12:30 PM – 01:30 PM Lunch & Exhibits
01:30 PM – 02:45 PM Session 3 - Multiple Myeloma - Newly Dx
Session Chair: Peter Forsberg, MD
01:30 PM – 01:45 PM Triplets or quadruplets - what is the right approach for newly diagnosed MM? - Peter Forsberg, MD
01:45 PM – 02:00 PM Transplant for MM - does it still have a role?
02:00 PM – 02:15 PM Maintenance approaches for MM - one, two, or more drugs?
02:15 PM – 02:45 PM Q & A and Case-Based Discussion
02:45 PM – 03:15 PM Break & Exhibits
03:15 PM – 03:45 PM Keynote Speech
03:45 PM – 05:00 PM Session 4 - AML/MDS
Session Chair: Hetty Carraway, MD
03:45 PM – 04:00 PM Management of Low Risk MDS: What is the Best Approach and or Sequence? ESAs, Telomerase inhibitors and Ligand Traps: OH MY! - Namrata Chandhok, MD
04:00 PM – 04:15 PM Frontline Therapy of AML in 2025 - Keith Pratz, MD
04:15 PM – 04:30 PM Treatment options for relapsed/refractory AML Triplets in AML. Where are we and what’s next?
04:30 PM – 04:45 PM What we need to know about Menin Inhibitors in AML/ALL. The New Kid on the Block
04:45 PM – 05:00 PM Q & A and Case-Based Discussion
DAY 2 – Saturday, September 20, 2025
07:00 AM – 08:00 AM Registration, Exhibits & Breakfast
08:00 AM – 08:20 AM Binaytara's Efforts in Improving Cancer Care Disparities - Binay Shah, MD, MHA
08:20 AM – 09:35 AM Session 5 - CLL
Session Chair: Nitin Jain, MD
08:20 AM – 08:35 AM BTK or BCL2i or Both for Frontline CLL
08:35 AM – 08:50 AM Pirtobrutinib, CAR T, and others. How to incorporate it in practice?
08:50 AM – 09:05 AM Richter transformation. What’s new?
09:05 AM – 09:35 AM Q & A and Case-Based Discussion - Mahesh Swaminathan, MD
09:35 AM – 10:05 AM Break & Exhibits
10:05 AM – 11:20 AM Session 6 - Low-Grade Lymphomas
Session Chairs: Sonali Smith, MD & Krish Patel, MD
10:05 AM – 10:20 AM Are bi-specifics really going to have a role in indolent lymphomas? - Vivek Patel, MD
10:20 AM – 10:35 AM Sequencing of treatments in 2L+ setting for follicular lymphoma
10:35 AM – 10:50 AM Updates in treatment of mantle cell lymphoma - Timothy Fenske, MD, MS
10:50 AM – 11:20 AM Q & A and Case-Based Discussion
11:20 AM – 12:20 PM Oral Abstract Session
12:20 PM – 01:20 PM Lunch, Exhibits
01:20 PM – 02:20 PM Poster Abstract Session
02:20 PM – 02:50 PM Keynote Speech
02:50 PM – 04:05 PM Session 7 - CML/MPN
Session Chair: Abhay Singh, MD, MPH
02:50 PM – 03:05 PM PV in 2025 - Andrew Kuykendall, MD
03:05 PM – 03:20 PM Clinical Management of MF in 2025 - Akriti Jain, MD
03:20 PM – 03:35 PM Role of Transplant in MF
03:35 PM – 04:05 PM Q & A and Case-Based Discussion
04:05 PM – 05:20 PM Session 8 - Multiple Myeloma - R/R
Session Chairs: Shaji Kumar, MD & Gurbakhash Kaur, MD
04:05 PM – 04:20 PM Management of early relapses in myeloma-choosing the right combination - Adeel Khan, MD
04:20 PM – 04:35 PM Integrating immunotherapies into the treatment of relapsed MM – CART, ADC, and bispecifics
04:35 PM – 04:50 PM Non-immune approaches for advanced myeloma - Gurbakhash Kaur, MD
04:50 PM – 05:20 PM Q & A and Case-Based Discussion - Amin Firoozmand, MD
05:20 PM Adjourn
HOTEL INFORMATION COMING SOON
IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:
All conflict of interest has been identified and mitigated for individuals in control of contents.
PLANNING COMMITTEE DISCLOSURE STATEMENT:
None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.
Shaji Kumar, MD
Navneet Majhail, MD, MS, FASTCT
Peter Forsberg
Shaji Kumar, MD
Nirav Shah, MD
Bhagirathbhai Dholaria, MD
Peter Forsberg
Akriti Jain, MD, FACP
amin firoozmand, MD, U.S. board-certified hematologist and medical oncologist with additional subspecialty training in bone marrow transplantation
Guru Subramanian Guru Murthy, MD, MS
Mahesh Swaminathan, MD
Available Credit
- 11.00 ABIM MOC IISuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 11.00 ACPE Pharmacy
The Binaytara Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
The ACPE Universal Activity Number assigned to the activity is
Participants must pass the post-test, complete course evaluation, and provide their NABP e-Profile ID number (ePID) and Date of Birth (MMDD) to Binaytara Foundation within 30-days of participating in the activity. Participants who do not complete these requirements within 30-days of participating in the Live activity will not be awarded the CEUs.
The Binaytara foundation may distribute a participation certificate containing information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor®.
After CPE units are processed by ACPE and NABP, pharmacists and pharmacy technicians will be able to login to a comprehensive electronic profile to access information about their completed CPE and Certificate Programs.
- 11.00 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 11.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 11.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 11.00 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 11.00 Contact Hours.
If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://www.sponsorships.binaytara.org/NashvilleSummit
Price
POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE:
All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place.
The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference. The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees.
If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.
Violating this policy will result in a fine equivalent to a general display fee for that conference.
NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:
If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:
- If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
- If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event.
- If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event.
Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.
CANCELLATION POLICY
You may cancel your enrollment at any time. Cancellation fees apply as below:
- 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
- No refunds will be issued if registration is canceled after that date.
No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.